MilliporeSigma

[Sodium thiosulfate--new hope for the treatment of calciphylaxis].

Duodecim; laaketieteellinen aikakauskirja (2011-10-07)
Maija Heiro, Leeni Mäkelä, Niina Koivuviita, Ilkka Manner, Risto Tertti, Ulla Hohenthal, Kaj Metsärinne
ABSTRACT

Calciphylaxis is a rare disease primarily affecting patients dependent on dialysis. It is characterised by small vessel media calcification leading to cutaneous ischemia and necrosis. The mortality rate is high with infection and sepsis being the most common causes of death. Calcium salts, vitamin D and high levels of serum calcium and phosphorus increase the risk of calciphylaxis. Current therapies including restoration of mineral homeostasis, wound care and pain control, are not entirely effective. Sodium thiosulfate, by dissolving calcium deposits, is a novel therapeutic choice for calciphylaxis. It has proved successful also in cases refractory to conventional treatment.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium thiosulfate, ≥99.99% trace metals basis
Sigma-Aldrich
Sodium thiosulfate, ReagentPlus®, 99%
Sigma-Aldrich
Sodium thiosulfate, purum p.a., anhydrous, ≥98.0% (RT)
Sigma-Aldrich
Sodium thiosulfate pentahydrate, BioXtra, ≥99.5%
Sigma-Aldrich
Sodium thiosulfate solution, 2 g/dL in deionized water
Sigma-Aldrich
Sodium thiosulfate pentahydrate, 99.999% trace metals basis
Sigma-Aldrich
Sodium thiosulfate pentahydrate, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Sodium thiosulfate pentahydrate, puriss., meets analytical specification of Ph. Eur., BP, USP
Sigma-Aldrich
Sodium thiosulfate pentahydrate, ACS reagent, ≥99.5%